Investee Profile

First-in-class and disruptive

Our approach targets a well-defined customer base: partners that seek to access external innovation. The signature of the investment sweet spot for us is thus primarily defined by their needs for first-in-class products that address a clear market need. In our portfolio companies thus we seek to develop technologies and products with disruptive potential. Preferably such assets are at preclinical stage, and even conceptual research stage such that, together with the (scientific) founders, a lean business case can be implemented at day one.

Scalable technologies

Capital-efficient leverage of a business case is a key driver in our strategy. This approach works particularly well when the potential of a technology is demonstrated through an exemplary development success. We therefore seek to execute a strategy around technologies that have the potential to form the basis for multiple products. Hence the value generated as part of our investment lies partly in the lead product that is based on such technology, but considerable additional value is created in validating the underlying technology.

"Dr. Stefan Herr is scientist and manager with a sense for impact and perspectives of new medicines. He carefully analyses products in regard to their efficacy and adverse events, their chances in the market and the feasibility of production. Dr. Herr approached me in a very professional manner for developing a new drug to treat ulcerative colitis. Within just one year, he helped to bring this novel drug to a state where an authority-relevant trial can now be started. He was successful in raising further funds to support this trial."
Prof. Wolfgang Stremmel, MD; University Hospital Heidelberg, Department of Gastroenterology, Founder Lipid Therapeutics, Heidelberg